Effects of cerivastatin and parathyroid hormone on the lumbar vertebra of aging male Sprague-Dawley rats.
Effects of cerivastatin and parathyroid hormone on the lumbar vertebra of aging male Sprague-Dawley rats.
复制标题
西立伐他汀和甲状旁腺激素对老年雄性斯普拉格道利大鼠腰椎的影响。
DOI：
10.1016/s8756-3282(02)00803-7
复制
发表时间：
2002
期刊：
影响因子：
4.1
通讯作者：
Kalu,DN
中科院分区：
文献类型：
--
作者：
Banu,J;Kalu,DN
男性和女性都会在晚年失去骨质(增龄性骨质流失)。这项研究的目的是确定西立伐他汀和甲状旁腺激素(PTH)是否可以防止男性增龄性骨丢失。采用老年雄性SD大鼠骨丢失作为男性增龄性骨丢失的模型。9月龄雄性SD大鼠分为6组：(1)基线对照组(研究开始时处死)；(2)年龄匹配对照组；(3)甲状旁腺激素(甲状旁腺激素，每天80μg/kg体重，连续5天/周)治疗；(4)低剂量西立伐他汀(每天0.2 mg/kg体重)治疗；(5)中剂量西立伐他汀(每天0.4 mg/kg体重)治疗；(6)大剂量西立伐他汀(每天0.8 mg/kg体重)治疗。第2-6组在9-15个月龄期间接受23周的治疗，并在23周结束时处死。采用外周定量CT(PQCT)对第四腰椎进行分析。结果表明，年龄匹配的对照组松质骨矿含量(CN。BMC)降低19%(p<；0.05)和松质骨密度Cn。BMD)与基线对照组相比下降了22%(p<；0.01)。三种剂量的西立伐他汀均可降低Cn。BMC和CN。与年龄匹配的对照组相比，骨密度有所下降，但这一下降在统计学上并不显著。甲状旁腺素治疗组：CN。BMC增加了5%(p<；0.0001)，CN增加了5%。与年龄匹配的对照组相比，骨密度增加了37%(p<；0.0001)。在年龄匹配的对照组，皮质骨矿物质含量(CT。BMC)和皮质骨密度(CT.BMD)与基线对照组相比略有下降，但并不显著。CT在西立伐他汀组中，骨密度在三个剂量中的任何一个都没有显著变化。在甲状旁腺素治疗组，CT。与年龄匹配的对照组相比，骨髓基质细胞增加了23%(p<；0.0001)。我们证实，雄性SD大鼠腰椎随着年龄的增长而失去骨质，结论是，所有剂量的西立伐他汀都不能阻止这种与年龄相关的骨质丢失。相反，甲状旁腺素防止了雄性SD大鼠椎骨中与年龄相关的骨丢失。
Both men and women lose bone at a late age (aging bone loss). The aim of this study was to determine whether cerivastatin and parathyroid hormone (PTH) can prevent aging bone loss in men. Bone loss in aged male Sprague-Dawley (SD) rats was used as a model for age-related bone loss in men. Nine-month-old male SD rats were divided into six groups: (1) baseline controls (killed at the beginning of the study); (2) age-matched controls; (3) parathyroid hormone (PTH; 80 μg/kg body weight per day for 5 days/week) treated; (4) low-dose cerivastatin (0.2 mg/kg body weight per day) treated; and (5) medium-dose cerivastatin (0.4 mg/kg body weight per day) treated; and (6) high-dose cerivastatin (0.8 mg/kg body weight per day) treated. Groups 2–6 were treated for 23 weeks between the ages of 9 and 15 months and killed at the end of 23 weeks. The fourth lumbar vertebra was analyzed using peripheral quantitative computed tomography (pQCT). It is shown that age-matched controls had decreased cancellous bone mineral content (Cn. BMC) by 19% (p < 0.05) and cancellous bone mineral density Cn. BMD) by 22% (p < 0.01) when compared with baseline controls. All three doses of cerivastatin resulted in lower Cn. BMC and Cn. BMD when compared with age-matched controls, but this decrease was not statistically significant. In the PTH-treated group, Cn. BMC increased by 5% (p < 0.0001) and Cn. BMD increased by 37% (p < 0.0001) when compared with age-matched controls. In age-matched controls, cortical bone mineral content (Ct. BMC) and cortical bone mineral density (Ct. BMD) decreased slightly, but not significantly, when compared with baseline controls. Ct. BMD did not change significantly at any of the three doses in the cerivastatin-treated groups. In the PTH-treated group, Ct. BMC increased by 23% (p < 0.0001) when compared with age-matched controls. We confirmed that male SD rats lose bone with aging in the lumbar vertebra, and it is concluded that cerivastatin, at all doses administered, did not prevent this age-related bone loss. In contrast, PTH prevented age-related bone loss in the vertebra of male SD rats.
登录
查看更多内容
人甲状旁腺激素 (1-34) 肽治疗 6 个月对切除卵巢的食蟹猴（食蟹猴）的效果。
影响因子：
4.1
作者：
Jerome,CP;Johnson,CS;Vafai,HT;Kaplan,KC;Bailey,J;Capwell,B;Fraser,F;Hansen,L;Ramsay,H;Shadoan,M;Lees,CJ;Thomsen,JS;Mosekilde,L
通讯作者：
Mosekilde,L
新型 HMG-CoA 还原酶抑制剂西立伐他汀的临床前安全性评价。
影响因子：
2.8
作者：
E. von Keutz;G. Schlüter
通讯作者：
G. Schlüter
人甲状旁腺激素 (1–34) 和 (1–84) 增加大鼠皮质骨的机械强度和厚度
影响因子：
6.2
作者：
C. Ejersted;T. Andreassen;H. Oxlund;P. Jørgensen;B. Bak;J. Häggblad;O. Tørring;M. Nilsson
通讯作者：
M. Nilsson
3-羟基-3-甲基戊二酰辅酶 A (HMG-CoA) 还原酶抑制剂对豚鼠的低胆固醇作用：阿托伐他汀与辛伐他汀。
影响因子：
5.8
作者：
K. Conde;Graciela Pineda;R. Newton;M. Fernández
通讯作者：
M. Fernández
影响因子：
4.8
作者：
KALU, DN;HARDIN, RH;YU, BP
通讯作者：
YU, BP